Full Press Release Details
Protalix BioTherapeutics
Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa
for the Treatment of Fabry Disease
Results Indicate Improvement in Kidney Function in Patients Switched from
agalsidase alfa (Replagal ) to pegunigalsidase alfa
deterioration trend in patients' kidney function on agalsidase alfa (Replagal ) was reversed to an
when switched to pegunigalsidase alfa (PRX-102)
with full Data to be held at the1st Canadian Symposium on Lysosomal Diseases 2018
CARMIEL, Israel, September 21, 2018 (GLOBENEWSWIRE)
-- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system,
ProCellEx , today announced positive preliminary data from the BRIDGE study of pegunigalsidase alfa (PRX-102) for
the treatment of Fabry disease. Additional data will be released at the 1st Canadian Symposium on Lysosomal Diseases 2018.
The BRIDGE study is an open
label switch over study evaluating the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase
alfa for at least 2 years and on a stable dose for at least 6 months. Patients are screened and evaluated over 3 months while continuing
on agalsidase alfa. Following the screening period, each patient was enrolled and switched from agalsidase alfa treatment to receive
intravenous (IV) infusions of PRX-102 1 mg/kg every two weeks for 12 months. Patients can receive PRX-102 infusions at a home care
setup based on the infusion tolerability.
Preliminary data from the first sixteen patients
enrolled in the trial demonstrated an improvement in kidney function when switched from agalsidase alfa (Replagal )
to pegunigalsidase alfa (PRX-102). Based on available historical serum creatinine and study 3 month screening period values for
approximately 2 years while treated with agalsidase alfa before switching to pegunigalsidase alfa treatment, the annualized estimated
glomerular filtration rate (eGFR) slope for patients on Replagal was (negative) --6.8ml/min/1.73m2 . The mean eGFR slope
for the same patients following six months of treatment with pegunigalsidase alfa (PRX-102) was changed to be (positive) of +3.7ml/min/1.73m2,
these results were statistically significant. Baseline characteristic of these patients were: mean estimated glomerular filtration
rate (eGFR) 75.40 and 86.03 mL/min/1.73m2 for males and females, with annualized eGFR slope of -8.0 and -5.1 mL/min/1.73m2/year,
The BRIDGE study is an open-label, single arm
switch-over study to assess the safety and efficacy of pegunigalsidase alfa, 1 mg/kg infused every two weeks, in 22 Fabry patients
currently treated with Replagal. Protalix anticipates completing patient enrollment in the BRIDGE trial in the fourth quarter of
PRX-102 is the Company's plant cell-expressed
recombinant, PEGylated, cross-linked -galactosidase-A for Fabry disease. In pre-clinical and clinical studies, PRX-102 demonstrated
higher stability in plasma, a longer half-life and higher exposure in Fabry disease patients, and a reduction in Gb3 in kidney
biopsies in treatment na ve Fabry patients.
BioTherapeutics, Inc.
Protalix is a biopharmaceutical
company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary
plant cell-based expression system, ProCellEx . Protalix's unique expression system presents a proprietary
method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured
by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May
2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the
worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment;
alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix partnered with Chiesi Farmaceutici S.p.A., both
in the United States and outside the United States, for the development and commercialization of pegunigalsidase
extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made
pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect,"
"anticipate, "believe," "estimate," "project," "plan," "should"
and "intend" and other words or phrases of similar import are intended to identify forward-looking statements.
These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience
and results to differ materially from the statements made. These statements are based on our current beliefs and expectations
as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of
a clinical trial may be different than the preliminary findings for the clinical trial. Factors that
might cause material differences include, among others: failure or delay in the commencement or completion of our preclinical and
clinical trials which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen
safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to monitor patients adequately
during or after treatment; inability or unwillingness of medical investigators and institutional review boards to follow our clinical
protocols; and lack of sufficient funding to finance clinical trials; the risk that the results of the clinical trials of our product
candidates will not support our claims of superiority, safety or efficacy, that our product candidates will not have the desired
effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to
maintain and manage our relationship with Chiesi Farmaceutici and any other collaborator, distributor or partner; risks related
to the amount and sufficiency of our cash and cash equivalents; risks related to the ultimate purchase by Funda o Oswaldo
Cruz of alfataliglicerase pursuant to the stated purchase intentions of the Brazilian Ministry of Health of the
stated amounts, if at all; risks related to the successful conclusion of our negotiations with the Brazilian Ministry of Health regarding
the purchase of alfataliglicerase generally; risks related to our commercialization efforts for alfataliglicerase in Brazil;
risks relating to the compliance by Funda o Oswaldo Cruz with its purchase obligations and related milestones
under our supply and technology transfer agreement; risks related to the amount and sufficiency of our cash and cash equivalents;
risks related to the amount of our future revenues, operations and expenditures; the risk that despite the FDA's grant of
fast track designation for pegunigalsidase alfa for the treatment of Fabry disease, we may not experience a faster development
process, review or approval compared to applications considered for approval under conventional FDA procedures; risks
related to the FDA's ability to withdraw the fast track designation at any time; risks relating to our ability to make scheduled
payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence
on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays
in our preparation and filing of applications for regulatory approval; delays in the approval or potential rejection of any applications
we file with the FDA or other health regulatory authorities, and other risks relating to the review process; our ability
to identify suitable product candidates and to complete preclinical studies of such product candidates; the inherent risks and
uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies
and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels
of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S. Securities
and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation
to update this information, except as may be required by law.
Marcy Nanus, Managing
Source: Protalix BioTherapeutics, Inc.